Pfizer and Novo Nordisk’s $10 Billion Obesity Drug War
Novo Nordisk has made a superior bid of up to $10 billion for obesity biotech Metsera, topping Pfizer’s revised $8.1 billion offer. Pfizer is fighting back with multiple lawsuits, calling the Danish drugmaker’s unsolicited bid anticompetitive in a rare industry showdown.